A Placebo-Controlled, Double-Blind, Randomized, Single Dose, Dose Escalating Trial in Healthy Men to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649

Trial Profile

A Placebo-Controlled, Double-Blind, Randomized, Single Dose, Dose Escalating Trial in Healthy Men to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2009

At a glance

  • Drugs Miravirsen (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Santaris Pharma
  • Most Recent Events

    • 23 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 09 Jan 2009 Planned end date changed from 1 Nov 2008 to 1 Mar 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top